Inhibition of caspase pathway as a treatment for lysosomal storage disorders

Abstract

Disclosed is a method of preventing, treating or reducing a lysosomal storage disorder (LSD) or a symptom thereof in a subject in need thereof comprising administering a therapeutically effective amount of caspase inhibitor to the subject. The therapeutically effective amount of caspase inhibitor may be a medicament or a composition for preventing, treating or reducing a lysosomal storage disorder (LSD) or a symptom thereof in a subject comprising a caspase inhibitor, and optionally a pharmaceutically acceptable carrier. One preferred caspase inhibitor is the pan caspase inhibitor Emricasan.

Dependencies are inferred from the claim text.